William Blair assumed coverage of Glaukos (GKOS) with an Outperform rating and no price target The firm sees a “solid” 2026 for the company, with pieces being put in place for significant sales acceleration in 2027. Glaukos is well positioned to “deliver best-in-class growth,” the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target raised to $131 from $123 at BTIG
- Wells sees potential upside after Glaukos’ iDose repeat dosing label approved
- Glaukos announces FDA approval of iDose TR NDA labeling supplement
- Glaukos price target raised to $160 from $115 at Stifel
- Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors